Last Updated : October 17, 2024
Details
Generic Name:
polatuzumab vedotin
Project Status:
Pending
Therapeutic Area:
large B-cell lymphoma (LBCL)
Manufacturer:
British Columbia Cancer Agency (BCCA)
Call for patient/clinician input open:
Brand Name:
Polivy Resubmission
Project Line:
Reimbursement Review
Project Number:
PC0397-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Polivy (polatuzumab vedotin) plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL, that are classified as activated B-cell-like (ABC) lymphoma subtype.
Submission Type:
Resubmission
Fee Schedule:
Pending
Indications:
Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T- cell/histiocyte rich LBCL.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : October 17, 2024